Sponsors (2)
The bill centralizes and improves biodefense analysis, guidance, and stakeholder input to strengthen preparedness, but it delays some public briefings and allows classified elements that can reduce near-term transparency and readiness while potentially increasing costs and regulatory burdens.
Scientists, researchers, state and local governments, and hospitals get coordinated analysis, clear voluntary best practices, and consultation resources to modernize biosafety and biosecurity, improving preparedness against engineering-biology risks.
Federal agencies (DOD, HHS, DHS, USDA) gain a flexible deadline tied to NDAA FY2027 enactment for required biodefense briefings, reducing the chance of missed interagency coordination caused by rigid calendar deadlines.
Congress will receive detailed legislative proposals and funding estimates to close biodefense gaps, enabling targeted investments and clearer oversight choices.
Delaying mandated briefings and permitting classified annexes reduces public and congressional transparency and can slow oversight and the timely identification/remediation of biodefense gaps, weakening near-term preparedness.
Taxpayers could face new or increased federal spending if Congress funds the recommended programs and authorities arising from the report and proposals.
Researchers, hospitals, and educational institutions may incur additional regulatory requirements, oversight, and administrative compliance costs to meet new biosafety and biosecurity standards.
Based on analysis of 3 sections of legislative text.
Moves a fixed briefing deadline to a date tied to enactment of the FY2027 NDAA and requires a detailed engineering-biology readiness analysis with recommendations and cost estimates.
Official title: Extend the requirement for annual briefings on National Biodefense Strategy and to require analysis and recommendations relating to the risks of engineering biology, and for other purposes.
Introduced April 21, 2026 by Timothy Michael Kaine · Last progress April 21, 2026
Revises the statutory deadline for an annual congressional briefing on the National Biodefense Strategy by replacing a fixed calendar date with a date defined relative to enactment of the FY2027 National Defense Authorization Act. Requires that the first biennial biodefense threat-assessment findings submitted after enactment include a detailed, unclassified analysis and recommendations to assess and improve U.S. readiness of national security and life-science research enterprises against engineering biology risks, developed with input from industry, academia, civil society, and unaffiliated life-science representatives, and may include a classified annex.